Research progress of defibrotide in the treatment and prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation
10.3760/cma.j.issn.1009-9921.2013.07.003
- VernacularTitle:去纤苷防治造血干细胞移植后肝静脉闭塞病的研究进展
- Author:
Xin YANG
;
Sizhou FENG
- Publication Type:Journal Article
- Keywords:
Hematopoietic stem cell transplantation;
Defibrotide;
Hepatic veno-occlusive disease
- From:
Journal of Leukemia & Lymphoma
2013;22(7):389-392
- CountryChina
- Language:Chinese
-
Abstract:
Hepatic veno-occlusive disease (HVOD) is a serious complication of hematopoietic stem cell transplantation.The mortality rate of severe HVOD (sHVOD) approaches 100 ％.Defibrotide (DF) is a polydisperse mixture of single-stranded oligonucleotides with antithrombotic and fibrinolytic properties.Numerous clinical trials have demonstrated its effectiveness and safety in the prevention and treatment of HVOD.This review focuses on the possible mechanisms of action of DF and its use in the prevention and treatment of HVOD.
